Navigation Links
Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level

SHANGHAI, Aug. 4 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd., (ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, announced today that it has moved its drug discovery collaboration with ELARA Pharmaceuticals to a new level. ChemPartner will provide fully integrated services in the areas of DMPK, pharmacology and toxicology for ELARA's lead oncology programs. Members of the joint project team from both sides will work closely together to design and execute a drug screening cascade.

"This new relationship is a natural result of the high quality services provided by ChemPartner," commented Dr. Joe Lewis, CEO and a founder of ELARA Pharmaceuticals. "The discovery support from ChemPartner helped our Hypoxia Signaling inhibitor program to move from academic discovery stage to early proof of concept. This led to a successful spin off from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Our new integrated relationship will enable ELARA to further leverage ChemPartner's strong R&D capabilities from discovery to early development phase. We anticipate a stronger strategic partnership down the road as our program progresses."

"We are very pleased to see that our services helped ELARA turn innovative research at a renowned academic institution into a venture funded drug discovery company," said Michael Hui, founder and CEO of ChemPartner. "Our partnership demonstrates the strength of ChemPartner's innovation driven and fully integrated R&D service platform"

About Shanghai ChemPartner

Founded in 2003, Shanghai ChemPartner Company Ltd. (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 80 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1000 scientists including over 80 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies.

Further information is available at .

About ELARA Pharmaceuticals

ELARA Pharmaceuticals is a spin-off of the European Molecular Biology Laboratory in Heidelberg, and was founded to translate basic research findings into novel cancer treatments.

The company is developing a portfolio of highly-potent orally-available inhibitors of the hypoxia signalling pathway. The lead compound shows an excellent in vivo profile and is expected to move into formal preclinical development this year.

Further information is available at .

SOURCE Shanghai ChemPartner Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007
2. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
3. Cinpathogen Brings Together Over 40 Shanghai Area Hospitals at the First Annual Cinpathogen Hematology Conference
4. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
5. Shanghai CRO Service Alliance Adds Clinical Development Capabilities
6. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
7. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
8. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
9. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
10. Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
11. Sundia Shortens CRO Shipment Delivery Time with Express Customs Clearance in Shanghai
Post Your Comments:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
Breaking Biology News(10 mins):